2024 Q2 Form 10-Q Financial Statement
#000177342724000018 Filed on May 02, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| Revenue | $59.73M | $21.01M | $0.00 |
| YoY Change | |||
| Cost Of Revenue | $2.453M | $1.202M | $0.00 |
| YoY Change | |||
| Gross Profit | $57.28M | $19.80M | $0.00 |
| YoY Change | |||
| Gross Profit Margin | 95.89% | 94.28% | |
| Selling, General & Admin | $57.84M | $60.11M | $44.18M |
| YoY Change | 23.09% | 36.08% | 61.42% |
| % of Gross Profit | 100.98% | 303.54% | |
| Research & Development | $44.36M | $53.62M | $33.52M |
| YoY Change | 23.72% | 59.95% | -1.7% |
| % of Gross Profit | 77.45% | 270.76% | |
| Depreciation & Amortization | $844.0K | $729.0K | $253.0K |
| YoY Change | 120.94% | 188.14% | 134.26% |
| % of Gross Profit | 1.47% | 3.68% | |
| Operating Expenses | $102.2M | $113.7M | $77.70M |
| YoY Change | 23.35% | 46.38% | 26.4% |
| Operating Profit | -$44.92M | -$93.93M | -$77.70M |
| YoY Change | -45.78% | 20.89% | 26.4% |
| Interest Expense | $5.002M | $6.546M | $4.478M |
| YoY Change | -0.56% | 46.18% | -3321.58% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $6.778M | $7.571M | $5.557M |
| YoY Change | 16.3% | 36.24% | 111040.0% |
| Pretax Income | -$39.92M | -$87.39M | -$73.42M |
| YoY Change | -48.78% | 19.02% | 18.8% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$39.92M | -$87.39M | -$73.42M |
| YoY Change | -48.77% | 19.02% | 18.8% |
| Net Earnings / Revenue | -66.83% | -416.0% | |
| Basic Earnings Per Share | -$0.54 | -$1.18 | -$1.18 |
| Diluted Earnings Per Share | -$0.54 | -$1.18 | -$1.18 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 74.09M shares | 73.79M shares | 62.50M shares |
| Diluted Shares Outstanding | 74.12M shares | 73.77M shares | 62.33M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $383.9M | $436.6M | $528.1M |
| YoY Change | -19.47% | -17.34% | 51.65% |
| Cash & Equivalents | $79.90M | $118.0M | $102.4M |
| Short-Term Investments | $304.0M | $318.6M | $425.7M |
| Other Short-Term Assets | $15.22M | $14.47M | $9.516M |
| YoY Change | 111.52% | 52.06% | 23.91% |
| Inventory | $7.718M | $5.216M | |
| Prepaid Expenses | |||
| Receivables | $24.50M | $15.53M | |
| Other Receivables | $0.00 | $0.00 | |
| Total Short-Term Assets | $431.3M | $471.8M | $537.7M |
| YoY Change | -10.87% | -12.25% | 51.05% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $18.21M | $18.26M | $15.73M |
| YoY Change | -27.18% | 16.12% | 160.61% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $7.389M | $9.165M | $5.714M |
| YoY Change | 53.49% | 60.4% | 124.43% |
| Other Assets | $15.38M | $14.77M | $2.891M |
| YoY Change | 325.8% | 410.86% | 10.05% |
| Total Long-Term Assets | $186.0M | $185.0M | $31.54M |
| YoY Change | 456.44% | 486.66% | -36.45% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $431.3M | $471.8M | $537.7M |
| Total Long-Term Assets | $186.0M | $185.0M | $31.54M |
| Total Assets | $617.3M | $656.8M | $569.2M |
| YoY Change | 19.33% | 15.4% | 40.34% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $7.889M | $7.011M | $6.990M |
| YoY Change | 128.4% | 0.3% | 322.61% |
| Accrued Expenses | $45.65M | $56.27M | $28.69M |
| YoY Change | 26.49% | 96.16% | 34.95% |
| Deferred Revenue | $0.00 | $4.652M | $1.690M |
| YoY Change | -100.0% | 175.27% | |
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $54.50M | $68.92M | $37.75M |
| YoY Change | 30.04% | 82.55% | 62.46% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Other Long-Term Liabilities | $6.101M | $20.48M | $24.52M |
| YoY Change | -74.56% | -16.5% | 345.82% |
| Total Long-Term Liabilities | $6.101M | $20.48M | $24.52M |
| YoY Change | -74.56% | -16.5% | 342.76% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $54.50M | $68.92M | $37.75M |
| Total Long-Term Liabilities | $6.101M | $20.48M | $24.52M |
| Total Liabilities | $60.60M | $89.39M | $62.27M |
| YoY Change | -8.02% | 43.55% | 116.41% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$1.022B | -$982.4M | -$643.4M |
| YoY Change | 41.74% | 52.69% | 81.6% |
| Common Stock | $7.000K | $7.000K | $6.000K |
| YoY Change | 16.67% | 16.67% | 20.0% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $556.7M | $567.4M | $506.9M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $617.3M | $656.8M | $569.2M |
| YoY Change | 19.33% | 15.4% | 40.34% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$39.92M | -$87.39M | -$73.42M |
| YoY Change | -48.77% | 19.02% | 18.8% |
| Depreciation, Depletion And Amortization | $844.0K | $729.0K | $253.0K |
| YoY Change | 120.94% | 188.14% | 134.26% |
| Cash From Operating Activities | -$41.79M | -$78.93M | -$61.82M |
| YoY Change | -12.59% | 27.68% | 26.97% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $12.23M | $577.0K | $2.977M |
| YoY Change | 295.89% | -80.62% | 24.72% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $12.51M | $22.04M | $101.6M |
| YoY Change | -80.4% | -78.3% | 252.58% |
| Cash From Investing Activities | $289.0K | $21.46M | $98.60M |
| YoY Change | -99.52% | -78.23% | 273.16% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 3.371M | -$552.0K | -$1.848M |
| YoY Change | -1085.67% | -70.13% | -808.05% |
| NET CHANGE | |||
| Cash From Operating Activities | -41.79M | -$78.93M | -$61.82M |
| Cash From Investing Activities | 289.0K | $21.46M | $98.60M |
| Cash From Financing Activities | 3.371M | -$552.0K | -$1.848M |
| Net Change In Cash | -38.13M | -$58.02M | $34.94M |
| YoY Change | -402.55% | -266.06% | -258.79% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$41.79M | -$78.93M | -$61.82M |
| Capital Expenditures | $12.23M | $577.0K | $2.977M |
| Free Cash Flow | -$54.01M | -$79.51M | -$64.80M |
| YoY Change | 6.12% | 22.71% | 26.86% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
605000 | usd |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
21006000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
0 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1202000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
0 | usd |
| CY2024Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
60113000 | usd |
| CY2023Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
44175000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
53622000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
33524000 | usd |
| CY2024Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
114937000 | usd |
| CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
77699000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-93931000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-77699000 | usd |
| CY2024Q1 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
7571000 | usd |
| CY2023Q1 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
5557000 | usd |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
7571000 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
5557000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-1025000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-1278000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-87385000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-73420000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.18 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.18 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.18 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.18 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
73768603 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
73768603 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
62326992 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
62326992 | shares |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-87385000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-73420000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-1304000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
605000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-1304000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
605000 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-88689000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-72815000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
558192000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
23395000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
83000 | usd |
| CY2023Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
1931000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-73420000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
506924000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
626219000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
30462000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
5945000 | usd |
| CY2024Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
6497000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-1304000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-87385000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
567440000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-87385000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-73420000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
729000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
253000 | usd |
| CY2024Q1 | swtx |
Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
|
400000 | usd |
| CY2023Q1 | swtx |
Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
|
286000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
30462000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
23395000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-1025000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-1278000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
9599000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
0 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2113000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
0 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1793000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1968000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
78000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
243000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-385000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-753000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-9625000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-10255000 | usd |
| CY2024Q1 | swtx |
Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
|
-568000 | usd |
| CY2023Q1 | swtx |
Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
|
-391000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-78930000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-61818000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
577000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2977000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
|
8235000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
|
2800000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
73642000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
68148000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
103917000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
172529000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
21463000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
98604000 | usd |
| CY2024Q1 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
6497000 | usd |
| CY2023Q1 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
1931000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
5945000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
83000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-552000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1848000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-58019000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
34938000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
176666000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
68068000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
118647000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
103006000 | usd |
| CY2024Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | usd |
| CY2023Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
2136000 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Nature of Operations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SpringWorks Therapeutics, Inc., together with its wholly-owned subsidiaries, collectively, the Company, is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology assets, including one approved product and several clinical candidates, and is advancing programs in both rare tumor types as well as highly prevalent, genetically defined cancers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OGSIVEO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(nirogacestat) is the Company’s first commercial product. OGSIVEO was approved by the United States Food and Drug Administration, or FDA, on November 27, 2023 for the treatment of adult patients with progressing desmoid tumors who require systemic treatment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred losses and negative operating cash flows since inception and had an accumulated deficit of $982.4 million and $895.0 million, and working capital of $402.9 million and $422.7 million, as of March 31, 2024 and December 31, 2023, respectively. In December 2023, the Company began to generate revenue from sales of OGSIVEO in the United States. For the three months ended March 31, 2024, the Company recorded net revenue of $21.0 million from the sales of OGSIVEO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash, cash equivalents and marketable securities of $573.0 million and $662.6 million as of March 31, 2024 and December 31, 2023, respectively. Based on the Company’s cash, cash equivalents and marketable securities as of March 31, 2024, management estimates that its current liquidity will enable it to meet operating expenses through at least twelve months after the date that these financial statements are issued.</span></div> | |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-982400000 | usd |
| CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-895000000 | usd |
| CY2024Q1 | swtx |
Working Capital
WorkingCapital
|
402900000 | usd |
| CY2023Q4 | swtx |
Working Capital
WorkingCapital
|
422700000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
573000000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
662600000 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses, valuation of equity-based compensation awards and variable consideration and other relevant inputs impacting the gross and net revenue recognition. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known. | |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
455069000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
2000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
115000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
454956000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
485344000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1191000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
0 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
486535000 | usd |
| CY2024Q1 | swtx |
Equity Method Investments Purchase Obligation Value
EquityMethodInvestmentsPurchaseObligationValue
|
12400000 | usd |
| CY2024Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
13927000 | usd |
| CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
26047000 | usd |
| CY2024Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
17121000 | usd |
| CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
15129000 | usd |
| CY2024Q1 | swtx |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
11250000 | usd |
| CY2023Q4 | swtx |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
11250000 | usd |
| CY2024Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
13975000 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
13143000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
56273000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
65569000 | usd |
| CY2024Q1 | us-gaap |
Litigation Settlement Expense
LitigationSettlementExpense
|
0 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
30462000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
23395000 | usd |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
15552386 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13488050 | shares |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |
